Details for 2020154250

Up to date per 03.04.2026

Actions

Title / Product Name

KREBSPATIENTENAUSWAHL ZUR VERABREICHUNG VON WNT-SIGNALWEG-INHIBITOREN UNTER VERWENDUNG EINER RNF43-MUTATIONSTATUS

Status

Deleted

Protection Type

European Patent

(AT-) Application Number

2020154250

EP Publication Number

3693476

E-Number

1622505

Language

PCT Number

Publication Date

12.08.2020 A

18.10.2023 B1

Registration Date

18.10.2023

AT Publication Date

15.11.2023

Application Date

22.02.2013

Registration Number

Priorities

28.02.2012

201261604290 P

IPC

C12Q 1/6886 20180101AFI20200617BHEP

Maximum Duration of Protection

22.02.2033

Owner

Novartis AGLichtstrasse 35 4056 BaselCH

Representative

No representatives present

Inventor

CONG, FengNovartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139US

HAO, HuaixiangNovartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139US

HSIEH, Hsin-iGenomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121US

LIU, JunGenomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121US

NG, NicholasGenomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121US

JIANG, XiaomoNovartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139US